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Abstract: Many species of tsetse flies (Diptera: Glossini-
dae) are infected with a virus that causes salivary gland
hypertrophy (SGH), and flies with SGH symptoms have a
reduced fecundity and fertility. The prevalence of SGH in
wild tsetse populations is usually very low (0.2%–5%), but
higher prevalence rates (15.2%) have been observed
occasionally. The successful eradication of a Glossina
austeni population from Unguja Island (Zanzibar) using an
area-wide integrated pest management approach with a
sterile insect technique (SIT) component (1994–1997)
encouraged several African countries, including Ethiopia,
to incorporate the SIT in their national tsetse control
programs. A large facility to produce tsetse flies for SIT
application in Ethiopia was inaugurated in 2007. To
support this project, a Glossina pallidipes colony originat-
ing from Ethiopia was successfully established in 1996,
but later up to 85% of adult flies displayed symptoms of
SGH. As a result, the colony declined and became extinct
by 2002. The difficulties experienced with the rearing of G.
pallidipes, epitomized by the collapse of the G. pallidipes
colony originating from Ethiopia, prompted the urgent
need to develop management strategies for the salivary
gland hypertrophy virus (SGHV) for this species. As a first
step to identify suitable management strategies, the virus
isolated from G. pallidipes (GpSGHV) was recently
sequenced and research was initiated on virus transmis-
sion and pathology. Different approaches to prevent virus
replication and its horizontal transmission during blood
feeding have been proposed. These include the use of
antiviral drugs such as acyclovir and valacyclovir added to
the blood for feeding or the use of antibodies against
SGHV virion proteins. In addition, preliminary attempts to
silence the expression of an essential viral protein using
RNA interference will be discussed.
Introduction
Tsetse flies (Glossina spp.) are the only cyclical vectors of two
debilitating diseases in Africa, sleeping sickness in humans (human
African trypanosomosis [HAT] caused by Trypanosoma brucei
gambiense and Trypanosoma brucei rhodesiense) and the cattle disease
nagana (African animal trypanosomosis [AAT] caused by T. b.
brucei, Trypanosoma congolense, and Trypanosoma vivax) [1,2]. Nagana,
and in certain areas also sleeping sickness, have been a major
obstacle to sub-Saharan African rural development and a severe
constraint to agricultural production [3]. Due to the lack of
effective vaccines and inexpensive drugs for HAT, and the
development of resistance of the AAT parasites against available
trypanocidal drugs [4], vector control remains the most efficient
strategy for the sustainable management of these diseases [5].
Successful eradication of Glossina austeni from the island of
Unguja, United Republic of Tanzania, was achieved using an
area-wide integrated pest management approach [6] that included
the release of sterile male flies [7]. As a consequence of this success,
programs were developed to apply this approach on the African
mainland and, in 1996, the government of Ethiopia embarked on
such a program with the aim of creating a zone free of Glossina
pallidipes in the Southern Rift Valley of Ethiopia [8,9]. This project
included the establishment of a laboratory colony of the target
species at the Insect Pest Control Laboratory (former Entomology
Unit) of the Joint FAO/IAEA Programme of Nuclear Techniques
in Food and Agriculture, Seibersdorf, Austria. Following its
successful establishment using pupae obtained from the target
field population in Ethiopia, the colony experienced a steady
decline over 2 years and finally became extinct. Investigations
revealed that up to 85% of both male and female flies had salivary
gland hypertrophy (SGH), a syndrome first described in wild
populations of G. pallidipes [10,11], but later detected in many
tsetse species from different African countries [12–19]. Jaenson
[20] was the first to identify a nuclear rod-shaped enveloped DNA
virus averaging 70 nm6640 nm in size as the causative agent.
This virus was also associated with testicular degeneration and
ovarian abnormalities [14,21–23] and affected the development,
survival, fertility, and fecundity of naturally [24] or experimentally
[25,26] infected flies. In tsetse field populations, mother-to-
offspring transmission, either trans-ovum or through infected milk
glands, is thought to be the most likely mode of transmission of the
virus (Figure 1) [15,23,27]. In laboratory-maintained flies,
horizontal transmission during in vitro feeding of blood provided
under a silicone membrane [28] was suspected to be a significant
route of virus infection, as each tray of blood may be used to feed
up to ten successive sets of fly cages. The complete genome of this
virus, now designated as the G. pallidipes salivary gland hypertro-
phy virus (GpSGHV), has been sequenced [29–32]. In order to
better understand the dynamics and mode of transmission of the
virus under laboratory rearing conditions, simple and reliable
PCR and qPCR methods were developed [33,34] and studies on
the dynamics of the virus in the laboratory colonies were initiated
[35].
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transmission, and dynamics of the GpSGHV in field populations
and laboratory colonies and describes potential strategies to
manage the virus’ impact in tsetse laboratory colonies. The
limitations that hinder the use of this virus as a biological control
agent for tsetse control are likewise discussed.
Methodology
Articles were identified by searching Medline through PubMed
using various combinations of terms, including ‘‘Salivary gland
hypertrophy virus’’, ‘‘tsetse’’, ‘‘SIT’’, ‘‘RNAi’’, ‘‘Antibodies
neutralization’’, and ‘‘Antiviral drugs’’. Research papers and case
reports from African countries were retrieved. Additional articles
were obtained by citation tracking of review and original articles.
The review also drew on conference proceedings and original
research conducted by the authors.
Epidemiology of SGHV in Tsetse Fly Field
Populations
Since the first record of SGH in 1934 by Whitnall [36], several
observations have given insight into the epidemiology of SGHV: (i)
the SGH prevalence in wild tsetse populations was in general low
(0.5%) but could reach up to 15% [13,17,20,37,38], (ii) most of the
wild flies with SGH were young flies [39], (iii) some flies with SGH
contained blood in the gut, indicating their ability to fly and feed
[17], (iv) males with SGH were almost always sterile and females
with SGH were only partially fertile [20], and (v) flies with SGH
had a shortened life span and often had difficulties feeding that
might be caused by a potential reduction of salivary gland
secretion and anticoagulant activity [26]. Furthermore, we
recently showed that in laboratory colonies (i) flies without SGH
could be asymptomatically infected [33,34], (ii) all the progeny
from females with SGH developed SGH, had high virus loads, and
were sterile [35], and (iii) in experimental field cage (dimensions:
diameter 2.9 m, height 2.0 m) studies, males with SGH showed
reduced mating competitivness, but remating frequency of females
was very low irrespective of the SGH status of the males in the first
mating (unpublished data).
Based on these previous observations, we constructed a model of
the vertical transmission of the virus in tsetse populations (Figure 1).
In each population, three types of flies (males and/or females) can
be present with respect to SGHV infection status: (a) healthy
(uninfected) flies, (b) asymptomatic infected flies (low virus load),
and (c) symptomatic infected flies (SGH and high virus load). With
respect to vertical transmission within these populations, symp-
tomatic males or females produce no progeny or sterile progeny,
respectively. The reduced life span of symptomatic flies along with
the sterility of their progeny (symptomatic mothers) and the
absence of progeny (symptomatic fathers) explain their low
prevalence (0.5%) in wild populations. The only way for the virus
to propagate through vertical transmission in wild fly populations
is by mating of asymptomatic infected flies either amongst each
other or with a healthy partner. Since the transmission is either
trans-ovum or through the infected milk glands [27], the progeny
status will depend, most probably, on the infection status of the
mothers. Preliminary PCR analyses of sampled wild tsetse from
different African areas revealed a high prevalence of asymptomatic
infected flies (unpublished data).
We have recently demonstrated that the virus released by
infected flies during feeding on an in vitro membrane feeding
system is an important source of contamination under laboratory
conditions [35] (Figure 2A). Under field conditions, tsetse flies take
their blood meals by feeding on wild or domestic animals. The
virus inoculum injected into animal by symptomatic or asymp-
tomatic infected flies during blood feeding is probably rapidly
diluted in the blood stream, and the probability of healthy flies
becoming infected by taking their blood meal on the same animal
is consequently very low. Furthermore, we recently demonstrated
that rabbits used to feed hundreds of asymptomatic infected flies
per week in laboratory conditions developed virus-specific
antibodies (unpublished data; Figure 2B). Assuming that the
amount of virus inoculated by repeated blood meals of infected
flies on the same animal is sufficient to develop such antibodies,
the virus particles injected into this animal might be neutralized.
So far, no investigations have been carried out in Africa to detect
SGHV-specific antibodies in the blood of domestic or wild
mammals on which tsetse flies normally feed.
Epidemiology of SGHV in Tsetse Fly Laboratory
Colonies
In contrast to field conditions, the prevalence of SGH in tsetse
laboratory colonies can increase up to 85% in certain cases.
This high prevalence was responsible for the collapse in 1987 of
the G. pallidipes colony established in 1983 at the Insect Pest
Control Laboratory collected from a population in the Lambwe
Valley, Kenya, and in 2002 of a colony established in 1996 from
Arba Minch, Ethiopia. The collapse of these colonies prompted
research to understand the modalities of virus transmission
under laboratory conditions and to develop potential virus
management strategies [33]. These investigations have shed
light on some crucial points in the virus transmission and
dynamics in tsetse colonies. Although vertical transmission from
mother to progeny also occurs in laboratory colonies, horizontal
transmission through the membrane feeding system seems to be
the main source of virus propagation (Figure 2A). Quantitative
PCR analyses revealed that asymptomatic and especially
symptomatic flies release large amounts of virus into the blood
at each meal. The high concentration of flies (75 flies per cage)
feeding at the same time on a restricted blood volume and
membrane surface and the successive feeding on the same
membrane for economic reasons of up to ten cages of flies
explains why, in laboratory colonies, 100% of adult flies were
infected [33]. Furthermore, flies with SGH do not have to face
the feeding difficulties found under field conditions, and even
with a reduced life span, they represent an important source of
virus contamination by releasing more virus into the blood diet
during feeding, leading to a progressive increase of symptomatic
flies in the colony.
Figure 1. Vertical transmission pattern of the SGHV. Red,
hypertrophied; blue, infected but not hypertrophied; black, uninfected.
*: Not confirmed, as no virus free colony is available. X: No progeny
(sterile). {: In each generation, a small proportion of the progeny of
infected asymptomatic females develop SGH.
doi:10.1371/journal.pntd.0001220.g001
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Many insect pathogenic viruses are currently used as biological
control agents, e.g., baculoviruses in lepidopteran hosts [40,41].
First investigations on SGHV led to the hypothesis that the virus
could be related to the baculovirus group [20], which raised the
possibility of its use as a biological control agent [42]. However,
further studies contradicted this view [29,30]. As mentioned
above, in wild tsetse populations the virus is essentially transmitted
vertically from mother to progeny and it is unlikely that horizontal
transmission plays a significant role during feeding on animal
hosts. Likewise, there is no evidence as yet for horizontal
transmission of the virus through contact between flies, mating,
or fecal contamination. These observations represent fundamental
limitations to using the virus as a biological control agent, which
requires an efficient way to deliver the virus to the target host.
From a purely practical point of view, the development of a
biopesticide to control tsetse flies based on SGHV faces several
technical challenges, a major one being the mass production of the
virus for field application and its formulation. Artificial infection of
healthy flies by feeding on contaminated blood is efficient, but the
symptoms of SGH corresponding to highest virus loads are
observed only in the next generation. Attempts to multiply the
SGHV in an alternative host (with a short life cycle and easy to
produce en masse, i.e., house flies) were not successful.
Furthermore, no in vitro system to multiply the virus in cell
culture is presently available. Finally, the formulation of a virus
suspension allowing the virus particles to retain their infectivity
under field conditions appears insuperable. Unlike baculoviruses,
SGHV does not produce occlusion bodies and the virus envelope
is extremely fragile. More than 90% of a purified virus suspension
looses its infectivity after 3 days at 4uC (unpublished data). These
difficulties make the use of this virus as a biological control agent
impractical.
Potential Virus Management Strategies
In view of our current understanding of the epidemiology of the
virus under laboratory conditions, two possible strategies to
manage the infection in a colony emerged: one based on the
reduction or inhibition of horizontal virus transmission, the other
on the reduction or inhibition of virus replication to avoid the
development of symptomatic infections in a colony. To mitigate
horizontal transmission in laboratory colonies, two approaches are
being explored: (a) changing the feeding protocol currently used in
colony rearing and/or (b) neutralizing the virus released during
blood feeding by adding virus-specific antibodies to the blood. To
reduce virus replication, two approaches have been tested: (c)
inhibiting replication with commercially available antiviral drugs
used to inhibit the DNA polymerase of similar viruses and (d)
developing RNA interference to silence essential virus specific
gene(s).
Development of a Virus Management System Based on
Modifying the Membrane Feeding Protocol
As mentioned above, the in vitro membrane feeding protocol
using successive feeds on the same membrane favors horizontal
virus transmission from infected to healthy colony flies. However,
feeding the flies on fresh, unused (i.e., clean) blood and membrane
at each meal (referred to as ‘‘clean feeding’’) resulted in a four log
reduction of the average virus load per fly (from 10
6 to 10
2 virus
Figure 2. Horizontal transmission of SGHV in G. pallidipes. (A) In vitro membrane feeding. (B) In vivo animal feeding. Red, flies with SGH; black,
uninfected flies.
doi:10.1371/journal.pntd.0001220.g002
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the establishment of a clean feeding colony by feeding the flies and
their progeny continuously on clean blood for more than 2 years.
Monitoring of the virus load and of the prevalence of SGH in this
colony showed a significant decrease of the virus load and an
absence of SGH syndrome in dissected flies (unpublished data).
Despite these very encouraging results, this approach is presently
too costly to be applied in large-scale mass rearing, and a
combination of clean feeding with other virus management
strategies is required. One potential option is using clean feeding
as a temporary filter to produce flies with low virus infection to be
used in large-scale rearing in combination with other virus
management methods [35].
Neutralizing Virus Infection by Mixing Virus-Specific
Antibodies with the Blood
Neutralizing antibodies are commonly used to control virus
infections in vertebrates [43–49] and also to protect shrimps
against a wispovirus [50]. Research on the use of neutralizing
antibodies produced against GpSGHV structural polypeptides to
potentially control horizontal transmission of the virus under in
vitro membrane feeding has been initiated. To that end, a
proteomic analysis of purified GpSGHV virus particles by liquid
chromatography tandem mass spectrometry (LC-MS/MS) was
undertaken. Sixty-one virion proteins were identified [51] and
SGHV-specific antibodies against envelope dominant proteins
were produced in rabbits by injecting purified recombinant
proteins or synthetic oligopeptides. Neutralizing tests of SGHV
infection using these antibodies are underway. After selecting the
antibody(ies) capable of neutralizing SGHV infection, the
corresponding protein(s) could be produced on large amounts
using bacterial or baculovirus expression systems and used to
produce antibodies in large animals. Appropriate concentrations
of neutralizing antibodies could then be added to the blood meal.
Combining the administration of antibodies with clean feeding or
other virus management methods could be effective in keeping the
virus infection at an acceptable level in tsetse colonies.
Blocking SGHV Replication Using Commercial Antiviral
Drugs
The discovery in the late 1970s that acyclic nucleoside analogs,
in particular acyclovir, could inhibit DNA replication of herpes
simplex virus (HSV) at concentrations far below those that affect
cellular DNA synthesis sparked a new era in antiviral chemother-
apy [52]. The underlying reason for the selectivity—that acyclovir
is specifically converted to the active metabolite by an HSV-
encoded thymidine kinase— was unexpected, but the potential for
exploiting viral enzymes to develop potent and specific antiviral
drugs was clearly demonstrated. Acyclovir subsequently became a
successful treatment for HSV-1 and HSV-2 [52,53]. After
completing the genome sequence of GpSGHV, the phylogenetic
analysis of its DNA polymerase amino acid sequence unexpectedly
revealed that it shares high similarity with herpes virus DNA
polymerase [29]. These similarities led us to speculate that
acyclovir might have an antiviral effect on GpSGHV replication.
Preliminary results indicated that per os treatment of flies by adding
acyclovir and valacyclovir to the blood meals significantly reduces
viral loads (unpublished data). Several other antiviral drugs are
currently available for DNA viruses that could be screened to
assess their impact on GpSGHV DNA replication. Several
parameters, such as (i) absence of any negative effect on fly
survival and productivity, (ii) significant reduction of virus loads,
(iii) suitable bioavailability when offered to the flies mixed with
blood, and (iv) affordable price will have to be considered for
selecting appropriate antiviral drugs for use in large-scale tsetse
rearing facilities. Administration of one or more antiviral drugs
could be combined with other methods of virus management.
Inhibiting SGHV Infection by Silencing Virus-Specific
Genes Using RNAi Technology
RNA interference (RNAi) has recently emerged as a powerful
tool for specific gene silencing in gene therapy [54,55]. Recent
studies have reported the successful use of dsRNAs produced in a
bacterial system as therapeutic agents for economically affordable
oral treatment of white spot syndrome disease of shrimps [56,57].
The potential of a similar approach based on the silencing of
essential GpSGHV gene(s) such as DNA polymerase, p74, or per os
infectivity factors to mitigate the SGHV infection is worth
evaluating.
In conclusion, the GpSGHV represents a threat to integrated
control programs against G. pallidipes that incorporate the release
Key Learning Points
N Tsetse salivary gland hypertrophy syndrome was report-
ed in wild tsetse populations from several species in
different countries with a prevalence of 0.5%–15%, while
in G. pallidipes laboratory colonies prevalence can reach
85%.
N Tsetse salivary gland hypertrophy virus (SGHV) cannot be
used as a biological control agent in tsetse control
program due to the virus characteristics, i.e., fragile
structure of virus particles and limited role of horizontal
virus transmission.
N GpSGHV seriously impedes rearing of G. pallidipes in
large-scale facilities by reducing fly productivity, which
hinders SIT programs for tsetse control.
N A virus management strategy based on reducing
horizontal virus transmission by changing the blood
feeding system currently used, neutralizing virus infec-
tion using virus-specific antibodies, and reducing virus
replication by administration of antiviral drugs or RNAi
technology is being developed.
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www.plosntds.org 4 August 2011 | Volume 5 | Issue 8 | e1220of sterile males because it reduces the productivity of G. pallidipes
colonies, which in certain circumstance has resulted in the collapse
of the colony. The virus cannot be used as a biological control
agent due to several limitations. So far the virus has been studied
from the point of view of its impact on G. pallidipes colonies in a
rearing facility, but the impact of the virus on release programs in
terms of competiveness, performance, and mating behavior of
symptomatic and asymptomatic infected male flies still requires
further study.
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